INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Aga...
July 15 2014 - 8:32AM
Business Wire
Glancy Binkow & Goldberg LLP reminds investors of Provectus
Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (NYSE:PVCT)
that all purchasers of Provectus securities between December 17,
2013 and May 22, 2014, inclusive (the “Class Period”) have until
July 28, 2014, to file a motion to be appointed as lead plaintiff
in the shareholder lawsuit.
Please contact us at (310) 201-9150, or at
shareholders@glancylaw.com to discuss this matter. If you inquire
by email please include your mailing address, telephone number and
number of shares purchased.
Provectus is a development-stage biopharmaceutical company
engaged in developing pharmaceuticals for oncology and dermatology
indications. The Company’s product line includes PV-10, which has
completed a Phase II study for metastatic melanoma and a Phase I
study for breast cancer, and is in various stages of clinical
development for certain other cancer indications. The Complaint
alleges that defendants misrepresented and/or failed to disclose
material adverse facts concerning the status of PV-10 and
preparations for a Phase III study of the drug.
On May 23, 2014, the Company announced that its application for
a designation of PV-10 as “Breakthrough Therapy” was denied by the
Food and Drug Administration. According to the Company, the FDA
denied the designation because the agency’s review indicated that
“the data upon which the Company based its request for designation
of PV-10 as a Breakthrough Therapy for the treatment of patients
with locally advanced cutaneous melanoma was insufficient to
demonstrate substantial improvement over existing therapies.”
If you are a member of the Class described above, you may move
the Court no later than July 28, 2014, to serve as lead plaintiff;
however, you must meet certain legal requirements. To be a member
of the Class, you need not take any action at this time; you may
retain counsel of your choice or take no action and remain an
absent member of the Class. If you wish to learn more about this
action or have any questions concerning this announcement or your
rights or interests with respect to these matters, please contact
Lesley Portnoy, Esquire, of Glancy Binkow & Goldberg LLP, 1925
Century Park East, Suite 2100, Los Angeles, California 90067, at
(646) 539-8980, by e-mail to shareholders@glancylaw.com, or visit
our website at http://www.glancylaw.com. If you inquire by email,
please include your mailing address, telephone number and number of
shares purchased.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
Glancy Binkow & Goldberg LLP, Los Angeles, CALesley Portnoy,
646-539-8980shareholders@glancylaw.comwww.glancylaw.com
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024